Management Strategy: Teva's CEO Richard Francis outlined a "pivot to growth strategy" focusing on innovative products, generics, and cost savings, reporting a 3% revenue increase to $4.5 billion in Q3 2025, with significant growth in AUSTEDO and other innovative products.
Financial Performance: The company achieved a non-GAAP EPS of $0.78, up 14% year-over-year, and raised its full-year revenue guidance to $16.8 billion to $17 billion, while also confirming ambitious revenue targets for AUSTEDO and UZEDY.
Pipeline and Outlook: Teva's late-stage pipeline includes promising assets with potential peak sales exceeding $11 billion, and management expressed confidence in achieving a 3% to 4% growth range for 2025, supported by ongoing transformation programs.
Risks and Analyst Sentiment: While management acknowledged risks from U.S. pharmaceutical tariffs and the TAPI divestiture, analysts showed increased confidence in Teva's innovative portfolio and cost-saving measures, reflecting a positive outlook on the company's strategic execution.
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
Truist
Buy
maintain
$32 -> $36
2026-01-07
Reason
Truist
Price Target
$32 -> $36
AI Analysis
2026-01-07
maintain
Buy
Reason
Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Jefferies
Buy
maintain
$29 -> $40
2026-01-06
Reason
Jefferies
Price Target
$29 -> $40
2026-01-06
maintain
Buy
Reason
Jefferies raised the firm's price target on Teva to $40 from $29 and keeps a Buy rating on the shares, which the analyst introduced as a top 2026 idea. The narrative should shift in 2026 and beyond with several pipeline catalysts, but key is convincing investors to ascribe a positive terminal value to reflect R&D productivity when historically none was given, says the analyst, who expects the R&D engine to "start bearing fruit in 2026."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA
Unlock Now
Piper Sandler
Overweight
upgrade
$30 -> $40
2025-12-22
Reason
Piper Sandler
Price Target
$30 -> $40
2025-12-22
upgrade
Overweight
Reason
Piper Sandler raised the firm's price target on Teva to $40 from $30 and keeps an Overweight rating on the shares. The firm is also making an argument for further multiple expansion. Teva's peer group is evolving as the mix continues to shift towards novel brand assets. In other words, the larger cap biopharma group is becoming a more appropriate peer group for Teva, Piper argues. As the firm layers in contribution from TL1A-directed treatment duvakitug in inflammatory bowel disease, and considers that Teva is not staring down significant loss of exclusivity exposure, it believes an even richer multiple is in order.
Goldman Sachs
Buy
maintain
$31 -> $35
2025-12-18
Reason
Goldman Sachs
Price Target
$31 -> $35
2025-12-18
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Teva to $35 from $31 and keeps a Buy rating on the shares.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
